Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 1.00 |
| ▸ | FAP | Q12884 | 3/20 | 0.78 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.78 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.78 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13316742 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL5803394 | 0.92 | DPP4 (0.87) | DPP4FAPDPP8DPP9 | |
| SCHEMBL5803391 | 0.92 | DPP4 (0.87) | DPP4FAPDPP8DPP9 | |
| SCHEMBL5803813 | 0.92 | DPP4 (0.87) | DPP4FAPDPP8DPP9 | |
| SCHEMBL6169022 | 0.92 | DPP4 (0.85) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL10063621 | 0.89 | DPP4 (0.79) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL6854089 | 0.89 | DPP4 (0.79) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL10063620 | 0.89 | DPP4 (0.79) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL5806717 | 0.88 | DPP4 (0.78) | DPP4FAPDPP8DPP9 | |
| Vildagliptin SCHEMBL16579 | 0.88 | DPP4 (1.00) | DPP4FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496877-B1 | METHOD AND COMPOSITION FOR TREATMENT OF DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND FLUID RETENTIVE STATES | NOVO NORDISK AS (DK) | 2008-10-01 | — | — | EP | claimed |
| US-20070197552-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | NOVO NORDISK A/S (DK) | 2007-08-23 | — | — | US | claimed |
| US-7064145-B2 | Inhibition of beta cell degeneration | NOVO NORDISK A/S (DK) | 2006-06-20 | — | — | US | claimed |
| EP-1496877-A2 | METHOD AND COMPOSITION FOR TREATMENT OF DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND FLUID RETENTIVE STATES | NOVO NORDISK A/S (DK) | 2005-01-19 | — | — | EP | claimed |
| US-20030236272-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | NOVO NORDISK A/S (DK) | 2003-12-25 | — | — | US | claimed |
| WO-2003057200-A2 | COMPOSITIONS COMPRISING INHIBITORS OF DPP-IV AND NEP ENZYMES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-07-17 | — | — | WO | claimed |
| EP-1259246-A2 | USE OF DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2002-11-27 | — | — | EP | claimed |
| US-20010025023-A1 | Inhibition of beta cell degeneration | NOVO NORDISK A/S (DK) | 2001-09-27 | — | — | US | claimed |
| WO-2001062266-A2 | USE OF DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2001-08-30 | — | — | WO | claimed |
| EP-3023095-B2 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2023-11-08 | — | — | EP | disclosed |
| EP-3738585-B1 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2022-12-14 | — | — | EP | disclosed |
| EP-3738585-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2020-11-18 | — | — | EP | disclosed |
| EP-3366283-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | Novartis AG (CH) | 2018-08-29 | — | — | EP | disclosed |
| EP-3023095-B1 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2018-05-16 | — | — | EP | disclosed |
| EP-1419173-A2 | PEPTIDES THAT BIND TO ATHEROSCLEROTIC LESIONS | Novartis AG (CH) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003099279-A1 | COMBINATION OF A DPP IV INHIBITOR AND A CARDIOVASCULAR COMPOUND | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003014145-A2 | PEPTIDES THAT BIND TO ATHEROSCLEROTIC LESIONS | NOVARTIS AG (CH) | 2003-02-20 | — | — | WO | disclosed |
| EP-1259246-A2 | USE OF DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2002-11-27 | — | — | EP | disclosed |
| US-20010025023-A1 | Inhibition of beta cell degeneration | NOVO NORDISK A/S (DK) | 2001-09-27 | — | — | US | disclosed |
| WO-2001062266-A2 | USE OF DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236272-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | DPP4, GIPR, GLP1R | DPP4 1/4885FAP 56/4885DPP8 8/4885 |
| US-20070197552-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | DPP4, GIPR, GLP1R | DPP4 1/4885FAP 56/4885DPP8 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.